title: Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?
authors.forename: Guillaume
authors.initials: G
authors.lastname: Martin-Blondel
authors.forename: Lise
authors.initials: L
authors.lastname: Cuzin
authors.forename: Pierre
authors.initials: P
authors.lastname: Delobel
authors.forename: Victor
authors.initials: V
authors.lastname: Cuvinciuc
authors.forename: Hervé
authors.initials: H
authors.lastname: Dumas
authors.forename: Muriel
authors.initials: M
authors.lastname: Alvarez
authors.forename: Patrice
authors.initials: P
authors.lastname: Massip
authors.forename: Bruno
authors.initials: B
authors.lastname: Marchou
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D003510:Cyclohexanes / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000188:drug therapy*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D000077592:Maraviroc; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc